{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:12:04Z","timestamp":1791969124715,"version":"4.3.4"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.breast.2024.103806","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T22:36:25Z","timestamp":1726180585000},"page":"103806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Role of [18F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-9175","authenticated-orcid":false,"given":"David","family":"Groheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia C.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritse M.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Ulaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Patrick","family":"Pilkington Woll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel T.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jeanne","family":"Vrancken Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Dibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2024.103806_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103806_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-013-2617-8","article-title":"Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up","volume":"140","author":"Falck","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","author":"Vaz","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib4","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2000.18.20.3495","article-title":"Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations","volume":"18","author":"Avril","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2002.20.2.379","article-title":"Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography","volume":"20","author":"Bos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib6","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma","volume":"56","author":"Hogan","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib7","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00259-015-3080-z","article-title":"Appearance of untreated bone metastases from breast cancer on FDG PET\/CT: importance of histologic subtype","volume":"42","author":"Dashevsky","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib8","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4. 2024. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"10.1016\/j.breast.2024.103806_bib9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib12","unstructured":"ESMO metastatic breast cancer living guidelines, v1.1 May 2023."},{"key":"10.1016\/j.breast.2024.103806_bib13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103806_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bulcan.2019.01.002","article-title":"[Update of the recommendations of good clinical practice for the use of PET in oncology]","volume":"106","author":"Sala\u00fcn","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","author":"Sala\u00fcn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib17","first-page":"1","article-title":"Breast cancer: initial workup and staging with FDG PET\/CT","author":"Groheux","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib18","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.24534","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT) imaging in the staging and prognosis of inflammatory breast cancer","volume":"115","author":"Alberini","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-007-9671-z","article-title":"Inflammatory breast cancer: PET\/CT, MRI, mammography, and sonography findings","volume":"109","author":"Yang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.2004.07.058","article-title":"18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer","volume":"22","author":"van der Hoeven","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2967\/jnumed.108.056010","article-title":"Retrospective study of 18F-FDG PET\/CT in the diagnosis of inflammatory breast cancer: preliminary data","volume":"50","author":"Carkaci","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ijrobp.2011.10.040","article-title":"Pretreatment staging positron emission tomography\/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs","volume":"83","author":"Walker","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2024.103806_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.112.106864","article-title":"18F-FDG PET\/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging","volume":"54","author":"Groheux","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-020-05631-4","article-title":"Discrepancy between FDG-PET\/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning","volume":"181","author":"Jacene","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.02.056","article-title":"Effect of (18)F-FDG PET\/CT imaging in patients with clinical Stage II and III breast cancer","volume":"71","author":"Groheux","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2024.103806_bib26","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","article-title":"Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures","volume":"26","author":"Fuster","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib27","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2010.07.034","article-title":"Detection of extra-axillary lymph node involvement with FDG PET\/CT in patients with stage II-III breast cancer","volume":"46","author":"Aukema","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1524-4741.2010.00987.x","article-title":"Additional value of PET-CT in staging of clinical stage IIB and III breast cancer","volume":"16","author":"Segaert","year":"2010","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2024.103806_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-011-1767-9","article-title":"18F-FDG PET\/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques","volume":"131","author":"Koolen","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/djs451","article-title":"Prognostic impact of 18fdg-PET-CT findings in clinical stage III and IIB breast cancer","volume":"104","author":"Groheux","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2024.103806_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","article-title":"18F-FDG PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations","volume":"41","author":"Cochet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib32","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2967\/jnumed.114.143297","article-title":"Retrospective analysis of 18F-FDG PET\/CT for staging asymptomatic breast cancer patients younger than 40 years","volume":"55","author":"Riedl","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-015-3630-6","article-title":"(18) F-FDG PET\/CT for initial staging in breast cancer patients - is there a relevant impact on treatment planning compared to conventional staging modalities?","author":"Krammer","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib34","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2967\/jnumed.111.093864","article-title":"The yield of 18F-FDG PET\/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study","volume":"52","author":"Groheux","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-014-2924-8","article-title":"Additional value of F-18 FDG PET\/CT for initial staging in breast cancer with clinically negative axillary nodes","volume":"145","author":"Jeong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MNM.0000000000000671","article-title":"Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET\/CT in preoperative and postoperative setting of breast cancer patients","volume":"38","author":"Evangelista","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.breast.2024.103806_bib158","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2024.103806_bib159","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s00259-017-3709-1","article-title":"18F-FDG-PET\/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer","volume":"44","author":"Ulaner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2471070567","article-title":"Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET\/CT","volume":"247","author":"Tateishi","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2024.103806_bib39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.12110853","article-title":"Performance of FDG PET\/CT in the clinical management of breast cancer","volume":"266","author":"Groheux","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2024.103806_bib43","unstructured":"https:\/\/www.abc-lisbon.org."},{"key":"10.1016\/j.breast.2024.103806_bib40","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2020.7592","article-title":"Clinical utility of 18F-FDG PET\/CT in staging localized breast cancer before initiating preoperative systemic therapy","volume":"18","author":"Ko","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2024.103806_bib41","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.6004\/jnccn.2020.7598","article-title":"Use of 18F-FDG PET\/CT as an initial staging procedure for stage II-III breast cancer: a multicenter value analysis","volume":"18","author":"Hyland","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2024.103806_bib42","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.23.00249","article-title":"Impact of 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer","volume":"41","author":"Dayes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib44","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1038\/s41598-023-32727-w","article-title":"2-[18F]FDG-PET\/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer","volume":"13","author":"Vogsen","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2024.103806_bib45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4048\/jbc.2012.15.4.441","article-title":"The effects of preoperative (18)F-FDG PET\/CT in breast cancer patients in comparison to the conventional imaging study","volume":"15","author":"Choi","year":"2012","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11307-005-0013-4","article-title":"Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET\/CT in restaged breast cancer patients","volume":"7","author":"Fueger","year":"2005","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.breast.2024.103806_bib47","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/cncr.22292","article-title":"The role of FDG-PET\/CT in suspected recurrence of breast cancer","volume":"107","author":"Radan","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.rct.0000284394.83696.42","article-title":"F-18-fluoro-2-deoxyglucose positron emission tomography\/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers","volume":"31","author":"Haug","year":"2007","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.breast.2024.103806_bib49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1259\/bjr\/17395663","article-title":"FDG-PET\/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy","volume":"80","author":"Veit-Haibach","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejrad.2007.10.021","article-title":"Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT","volume":"65","author":"Schmidt","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib51","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejrad.2008.10.031","article-title":"Integrated contrast-enhanced diagnostic whole-body PET\/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer","volume":"73","author":"Dirisamer","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejso.2009.11.009","article-title":"The role of FDG PET\/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques","volume":"36","author":"Aukema","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib53","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ejrad.2010.04.029","article-title":"18F-FDG-PET\/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study","volume":"80","author":"Grassetto","year":"2011","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00259-010-1626-7","article-title":"Tumour markers and FDG PET\/CT for prediction of disease relapse in patients with breast cancer","volume":"38","author":"Evangelista","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/cncr.25727","article-title":"Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET\/CT imaging and impact on patient management","volume":"117","author":"Champion","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/MNM.0b013e3283516716","article-title":"Clinical utility of F-18 FDG PET\/CT in recurrent breast carcinoma","volume":"33","author":"Manohar","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.breast.2024.103806_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115127","article-title":"Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in the post-therapy surveillance of breast cancer","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2024.103806_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1470-7330-14-13","article-title":"The utility of 18 F-FDG PET\/CT for suspected recurrent breast cancer: impact and prognostic stratification","volume":"14","author":"Cochet","year":"2014","journal-title":"Cancer Imag"},{"key":"10.1016\/j.breast.2024.103806_bib59","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.2015.8","article-title":"Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase","volume":"112","author":"Di Gioia","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/ar.2011.110245","article-title":"FDG-PET\/CT in the diagnosis of recurrent breast cancer","volume":"53","author":"Murakami","year":"2012","journal-title":"Acta Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13550-021-00833-3","article-title":"Benefits and harms of implementing [18F]FDG-PET\/CT for diagnosing recurrent breast cancer: a prospective clinical study","volume":"11","author":"Vogsen","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.breast.2024.103806_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-004-3291-7","article-title":"A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases","volume":"90","author":"Isasi","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib63","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00432-009-0746-6","article-title":"FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis","volume":"136","author":"Pan","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14500","article-title":"A systematic review of positron emission tomography (PET) and positron emission tomography\/computed tomography (PET\/CT) for the diagnosis of breast cancer recurrence","volume":"14","author":"Pennant","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.breast.2024.103806_bib65","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/MNM.0000000000000573","article-title":"Diagnostic efficacy of 18F-FDG-PET or PET\/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis","volume":"37","author":"Xiao","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.breast.2024.103806_bib66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0b013e31824850b0","article-title":"Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis","volume":"37","author":"Evangelista","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2024.103806_bib67","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1148\/rg.27si075517","article-title":"FDG PET, PET\/CT, and breast cancer imaging","volume":"27","author":"Rosen","year":"2007","journal-title":"Radiographics"},{"key":"10.1016\/j.breast.2024.103806_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2214\/ajr.183.2.1830479","article-title":"Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer","volume":"183","author":"Eubank","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.breast.2024.103806_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1159\/000507707","article-title":"How useful are tumor markers in detecting metastases with FDG-PET\/CT during breast cancer surveillance?","volume":"98","author":"Corso","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.breast.2024.103806_bib70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00259-014-2941-1","article-title":"Prognostic impact of 18F-FDG PET\/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"42","author":"Groheux","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib71","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.2000.18.8.1676","article-title":"Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy","volume":"18","author":"Smith","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib72","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2000.18.8.1689","article-title":"Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer","volume":"18","author":"Schelling","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib73","first-page":"1806","article-title":"Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy","volume":"44","author":"Mankoff","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib74","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.05.7406","article-title":"Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography","volume":"24","author":"Rousseau","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib75","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-007-0459-5","article-title":"[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy","volume":"34","author":"Berriolo-Riedinger","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-006-9316-7","article-title":"Monitoring primary breast cancer throughout chemotherapy using FDG-PET","volume":"102","author":"McDermott","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib77","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1200\/JCO.2007.15.4385","article-title":"Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer","volume":"26","author":"Dunnwald","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib78","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2008.17.2650","article-title":"Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose","volume":"27","author":"Schwarz-Dose","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib79","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00330-009-1303-z","article-title":"The role of 18F-FDG PET\/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer","volume":"19","author":"Kumar","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib80","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00259-009-1116-y","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"36","author":"Duch","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib81","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr2591","article-title":"The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET","volume":"12","author":"Schneider-Kolsky","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2024.103806_bib82","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/1471-2407-11-452","article-title":"Early metabolic response using FDG PET\/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy","volume":"11","author":"Keam","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib83","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10549-011-1832-4","article-title":"Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course","volume":"131","author":"Kolesnikov-Gauthier","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1148\/radiol.12111177","article-title":"Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET\/CT and dynamic contrast-enhanced MR imaging--prospective assessment","volume":"263","author":"Tateishi","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2024.103806_bib85","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ejso.2013.08.025","article-title":"Can FDG-PET\/CT predict early response to neoadjuvant chemotherapy in breast cancer?","volume":"39","author":"Andrade","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib86","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1245\/s10434-019-07325-8","article-title":"Significance of metabolic tumor volume at baseline and reduction of mean standardized uptake value in 18F-FDG-PET\/CT imaging for predicting pathological complete response in breast cancers treated with preoperative chemotherapy","volume":"26","author":"Higuchi","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib87","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4274\/mirt.galenos.2022.44154","article-title":"The value of 18F-FDG PET\/CT imaging in the evaluation of interim neoadjuvant chemotherapy response in locally advanced breast cancer","volume":"31","author":"Tatar","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1016\/j.breast.2024.103806_bib88","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.111.096834","article-title":"Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET\/CT: comparison with angiogenesis markers and prognostic factors","volume":"53","author":"Cochet","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib89","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2967\/jnumed.112.108837","article-title":"Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"54","author":"Hatt","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib90","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2967\/jnumed.116.172759","article-title":"18F-FDG PET-derived tumor blood flow changes after 1 cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer","volume":"57","author":"Humbert","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib91","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.117.203075","article-title":"Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition18FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy","author":"Humbert","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib92","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.115.163907","article-title":"18F-FDG PET\/CT for the early evaluation of response to neoadjuvant treatment in triple-negative breast cancer: influence of the chemotherapy regimen","volume":"57","author":"Groheux","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib93","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1093\/annonc\/mds071","article-title":"Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes","volume":"23","author":"Humbert","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib94","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","article-title":"FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer","volume":"22","author":"Koolen","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103806_bib95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00259-013-2515-7","article-title":"Sequential (18)F-FDG PET\/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy","volume":"41","author":"Koolen","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2967\/jnumed.111.094045","article-title":"Triple-negative breast cancer: early assessment with 18F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse","volume":"53","author":"Groheux","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib97","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2012.12.024","article-title":"Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy","volume":"49","author":"Zucchini","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib98","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.ejca.2014.04.020","article-title":"Early assessment with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer","volume":"50","author":"Groheux","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib99","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-0384","article-title":"Identification of biomarkers including 18FDG-PET\/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer","author":"Humbert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2024.103806_bib100","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jamaoncol.2021.1932","article-title":"Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial","volume":"7","author":"Hatschek","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib101","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2013.469","article-title":"HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment","volume":"109","author":"Groheux","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib102","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00259-014-2739-1","article-title":"HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy","volume":"41","author":"Humbert","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib103","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(14)70475-9","volume":"15","author":"Coudert","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib104","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib105","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2024.103806_bib106","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2024.103806_bib107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00259-010-1660-5","article-title":"Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET\/CT: defining a clinical aim","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib108","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-015-3295-z","article-title":"(18)F-FDG PET\/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials","volume":"43","author":"Groheux","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib109","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3816\/CBC.2000.n.014","article-title":"Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients","volume":"1","author":"Gennari","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib110","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1076-6332(03)80461-0","article-title":"Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy","volume":"9","author":"Stafford","year":"2002","journal-title":"Acad Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib111","first-page":"1144","article-title":"Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET","volume":"46","author":"Dose Schwarz","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib112","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-06-0383","article-title":"Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer","volume":"12","author":"Couturier","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2024.103806_bib113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9435-1","article-title":"Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)","volume":"105","author":"Specht","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib114","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2007.11.2854","article-title":"Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography\/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer","volume":"25","author":"Du","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib115","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.clon.2010.05.021","article-title":"Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients","volume":"22","author":"Huyge","year":"2010","journal-title":"Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib116","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib117","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2014.60.0353","volume":"33","author":"Lin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib118","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003753","article-title":"Effectiveness of 18F-FDG-PET\/CT vs bone scintigraphy in treatment response assessment of bone metastases in breast cancer","volume":"95","author":"Al-Muqbel","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2024.103806_bib119","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2967\/jnumed.115.166629","article-title":"The impact that number of analyzed metastatic breast cancer lesions has on response assessment by 18F-FDG PET\/CT using PERCIST","volume":"57","author":"Pinker","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib120","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-19-1658","article-title":"Impact of FDG PET imaging for expanding patient eligibility and measuring treatment response in a genome-driven basket trial of the pan-HER kinase inhibitor, neratinib","volume":"25","author":"Ulaner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2024.103806_bib121","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/diagnostics11040723","article-title":"FDG-PET\/CT for response monitoring in metastatic breast cancer: the feasibility and benefits of applying PERCIST","volume":"11","author":"Vogsen","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.breast.2024.103806_bib122","first-page":"155","article-title":"Early assessment of tumor response using 18F-FDG PET\/CT after one cycle of systemic therapy in patients with recurrent and metastatic breast cancer","volume":"25","author":"Kitajima","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib123","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00259-011-1981-z","article-title":"Assessment of response to endocrine therapy using FDG PET\/CT in metastatic breast cancer: a pilot study","volume":"39","author":"Mortazavi-Jehanno","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib124","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12149-018-01323-8","article-title":"Response evaluation with 18F-FDG PET\/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice","volume":"33","author":"Taralli","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib125","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000516422","article-title":"[18F]-Fluorodeoxyglucose positron emission tomography\/CT to assess the early metabolic response in patients with hormone receptor-positive HER2-negative metastasized breast cancer treated with cyclin-dependent 4\/6 kinase inhibitors","volume":"44","author":"Seifert","year":"2021","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.breast.2024.103806_bib126","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1097\/RLU.0000000000004177","article-title":"18F-FDG PET\/CT metabolic response with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with cyclin-dependent 4\/6 kinase inhibitors","volume":"47","author":"Filizoglu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib127","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00259-018-4223-9","article-title":"Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET\/CT with whole-body MRI with diffusion-weighted imaging","volume":"46","author":"Azad","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib128","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2024.103806_bib129","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib130","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib131","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40644-022-00512-z","article-title":"Perspectives on joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards for [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors","volume":"22","author":"Lopci","year":"2022","journal-title":"Cancer Imag"},{"key":"10.1016\/j.breast.2024.103806_bib132","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib133","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib134","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","article-title":"Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12282-008-0065-9","article-title":"Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy","volume":"16","author":"Uematsu","year":"2009","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib136","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2967\/jnumed.108.052050","article-title":"Breast cancer staging in a single session: whole-body PET\/CT mammography","volume":"49","author":"Heusner","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib137","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fonc.2020.01301","article-title":"Progress and future trends in PET\/CT and PET\/MRI molecular imaging approaches for breast cancer","volume":"10","author":"Ming","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2014.09.008","article-title":"Simultaneous whole-body (18)F-FDG PET-MRI in primary staging of breast cancer: a pilot study","author":"Taneja","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib139","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clbc.2013.12.004","article-title":"Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis","volume":"14","author":"Caldarella","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1200\/JCO.2004.04.148","article-title":"Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group","volume":"22","author":"Wahl","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdl425","article-title":"A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases","volume":"18","author":"Veronesi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib142","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2011.38.1103","article-title":"Prospective study of 2-[18F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study","volume":"30","author":"Pritchard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib143","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2967\/jnumed.110.081711","article-title":"The sentinel node procedure in breast cancer: nuclear medicine as the starting point","volume":"52","author":"Hindi\u00e9","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2024.103806_bib144","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejso.2011.01.003","article-title":"Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis","volume":"37","author":"Cooper","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.breast.2024.103806_bib145","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/jcm10071543","article-title":"Pretherapeutic imaging for axillary staging in breast cancer: a systematic review and meta-analysis of ultrasound, MRI and FDG PET","volume":"10","author":"Le","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.breast.2024.103806_bib146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2407-8-165","article-title":"Utility of 18F-fluoro-deoxyglucose emission tomography\/computed tomography fusion imaging (18F-FDG PET\/CT) in combination with ultrasonography for axillary staging in primary breast cancer","volume":"8","author":"Ueda","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2024.103806_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15040","article-title":"Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation","volume":"15","author":"Cooper","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.breast.2024.103806_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260804","article-title":"Prospective comparison of CT and 18F-FDG PET\/MRI in N and M staging of primary breast cancer patients: initial results","volume":"16","author":"Bruckmann","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2024.103806_bib149","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00259-021-05502-0","article-title":"Comparison of nodal staging between CT, MRI, and [18F]-FDG PET\/MRI in patients with newly diagnosed breast cancer","volume":"49","author":"Morawitz","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2024.103806_bib150","doi-asserted-by":"crossref","first-page":"i1152","DOI":"10.1136\/bmj.i1152","article-title":"The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines","volume":"352","author":"Brouwers","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2024.103806_bib151","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103806_bib152","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103806_bib153","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103806_bib154","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2024.103806_bib155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejrad.2015.12.010","article-title":"Evaluation of 18F-FDG PET\/MRI, 18F-FDG PET\/CT, MRI, and CT in whole-body staging of recurrent breast cancer","volume":"85","author":"Sawicki","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.breast.2024.103806_bib156","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1148\/radiol.2016151155","article-title":"Comparison of whole-body (18)F FDG PET\/MR imaging and whole-body (18)F FDG PET\/CT in terms of lesion detection and radiation dose in patients with breast cancer","volume":"281","author":"Melsaether","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2024.103806_bib157","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.1007\/s00330-021-07956-0","article-title":"Prospective comparison of the diagnostic accuracy of 18F-FDG PET\/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients","volume":"31","author":"Bruckmann","year":"2021","journal-title":"Eur Radiol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T23:59:09Z","timestamp":1733183949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624001371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":159,"alternative-id":["S0960977624001371"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103806","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of [18F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103806"}}